Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2341 to 2355 of 9128 results

  1. GNT0006 ATA-100 for treating FKRP-related limb girdle muscular dystrophy R9 [TSID12384]

    Awaiting development Reference number: GID-TA12009 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. VX-522 for treating cystic fibrosis unresponsive to CFTR modulators when there are 2 mutations in the CFTR gene [TSID12431]

    Awaiting development Reference number: GID-TA12478 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Depemokimab for treating eosinophilic granulomatosis with polyangiitis [TSID12383]

    Awaiting development Reference number: GID-TA12007 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Teplizumab for delaying progression of stage 3 type 1 diabetes in people 8 years and over [TSID12403]

    Awaiting development Reference number: GID-TA12037 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Datopotamab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after osimertinib [TSID12418]

    Awaiting development Reference number: GID-TA12469 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Sacituzumab tirumotecan for treating endometrial cancer after platinum-based chemotherapy and immunotherapy

    Awaiting development Reference number: GID-TA12448 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Glofitamab for treating relapsed or refractory mantle cell lymphoma

    Awaiting development Reference number: GID-TA12447 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Garetosmab for preventing heterotopic ossification and flare ups associated with fibrodysplasia ossificans progressiva [ID3772]

    Awaiting development Reference number: GID-TA12522 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Lutikizumab for treating moderate to severe hidradenitis suppurativa in people 12 years and over

    Awaiting development Reference number: GID-TA12446 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]

    Awaiting development Reference number: GID-TA11686 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)

    In development Reference number: GID-NG10450 Expected publication date:  20 August 2026

    NICE guideline
    In development

  12. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development Reference number: GID-TA11454 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663]

    Awaiting development Reference number: GID-TA11883 Expected publication date:  23 September 2027

    Technology appraisal guidance
    Awaiting development

  14. Lotilaner for treating moderate to severe demodex blepharitis

    Awaiting development Reference number: GID-TA12520 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Headaches (update): Prophylactic treatment of migraine - Candesartan

    In development Reference number: GID-NG10472 Expected publication date:  17 February 2027

    NICE guideline
    In development